Bayer
NEWS
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
Last year, the FDA’s Center for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of them, were supported with genomic data.
BioSpace connected with Theodore Laetsch, M.D., lead investigator of the pediatric larotrectinib trial (SCOUT), to gain more insight into the drug, the trial and how patients’ lives are being affected.
Cambridge, Massachusetts’ Kendall Square just got a little more crowded following the announcement that life sciences giant Bayer opened its new Research and Innovation Center.
From search engines to social media, algorithms are quickly becoming a part of everyday life, and companies like Bayer, MIT and others are using them to their advantage.
BioSpace caught up with Tara Frenkl and Nelson Ambrogio ahead of ASCO to discuss Bayer’s goal of becoming a top 10 oncology company by 2030.
Today, scientist-founders are likely to remain in charge, shepherding the companies they founded to the next iteration. BioSpace spoke with one such founder, Mammoth Biosciences’ Trevor Martin.
Private investors, governmental institutions and longtime life sciences investors provided funding to develop therapies for cancers, dermatological problems and acute ischemic strokes.
JOBS
IN THE PRESS